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EUROMAXimizing benefits of bleeding risk but
catching a MATRIX of HEAT for stent thrombosis*Jonathan Soverow a,*, Ziad Ali a,b
a Center for Interventional Vascular Therapy, Division of Cardiology, New York Presbyterian Hospital and Columbia
University, New York, NY, USA
b Cardiovascular Research Foundation, New York, NY, USAIn this issue, Kaul et al describe their single center experience
in 1453 patients using bivalirudin or heparin ± glycoprotein
IIb/IIIa inhibitors (GPI) for percutaneous coronary intervention
(PCI). Though limited by its design, this “real world” observa-
tional study from an underrepresented patient population
reports a lower rate of bleeding, possiblemortality benefit, and
neutral stent thrombosis with the use of bivalirudin. These
data add to a mixed body of evidence supporting the safe,
effective use of bivalirudin for PCI and its particular advan-
tages in properly selected patients.
Bivalirudin is a synthetic polypeptide direct thrombin in-
hibitor given by intravenous infusion. Its pharmacokinetics
allow for rapid onset/offset of themedication, permitting tight
control of the timing of anticoagulation. Peak plasma con-
centrations occur within 2 min, are maintained with minimal
interpatient variability, and combined renal and proteolytic
clearance lead to an elimination half-life of 25e30 min in pa-
tients with normal kidney function.1
There are now a wealth of clinical data on the use of this
agent. It has been studied in over 24,000 patients, including at
least 13 large randomized trials of patients with acute coro-
nary syndromes.2 One of the largest of these trials, the
Harmonizing Outcomes with Revascularization and Stents in
Acute Myocardial Infarction (HORIZONS-AMI) trial, provided
an initial glimpse of the impact of bivalirudin's rapid clear-
ance.3 The trial randomized 3602 patients with ST-segment
elevation myocardial infarction (STEMI) to bivalirudin or
heparin þ GPI. The use of bivalirudin improved thirty-day* This editorial is pertaining to the article: Comparison of Anti-Thro
Patients Undergoing PCI in a real world setting.
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0019-4832/Copyright © 2015, Cardiological Society of India. All rightsmajor bleeding (4.9% vs. 8.3%, p < 0.001) and overall mortal-
ity rates (2.1% vs. 3.1%, p ¼ 0.047). However, there was
an increased risk of acute stent thrombosis within 24 h,
though differences in stent thrombosis rates equilibrated by
30 daysdsuggesting the presence of a vulnerable period
between the elimination of bivalirudin and effect of oral
antiplatelet therapy.
At least two other large trialsdHow Effective are Antith-
rombotic Therapies in Primary Percutaneous Coronary Inter-
vention (HEAT-PPCI) and European Ambulance Acute
Coronary Syndrome Angiography (EUROMAX)d and a recent
meta-analysis have echoed these outcomes: lower bleeding
and higher acute (<24 h) but not subacute (24 h-30days) stent
thrombosis.2,4,5 By limiting the use of GPI, these two trials also
raised questions about bivalirudin's superiority (there was no
mortality benefit) to heparin alone.
But a more recent trial has provided some insight into the
increased stent thrombosis rates and a path towards pre-
venting it. The Bivalirudin in Acute Myocardial Infarction vs.
Heparin and GPI Plus Heparin Trial (BRIGHT) randomized
2194 patients with ACS to bivalirudin, heparin, or
heparin þ GPI in 1:1:1 fashion.6 As part of the study protocol,
bivalirudin infusion was continued post-PCI for a minimum
of 30 min and maximum of 4 h at a rate of 1.75 mg/kg/h,
with a discretionary extension at low dose (0.2 mg/kg/h) up
to 20 h. With a median 3 h of post-infusion, BRIGHT revealed
no numerical or statistical increase in stent thrombosis
rates but continued reduction in bleeding with bivalirudinmbotic Strategies using Bivalirudin, Heparin plus GPI and UFH for
reserved.
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group analysis of those patients who received a prolonged
infusion of high-dose bivalirudin in the EUROMAX trial also
revealed similar stent thrombosis and reduced bleeding
rates compared with heparin alone; of note, there was no
improvement in stent thrombosis rates with prolonged
infusion of low-dose bivalirudin.7 The present study by Kaul
et al followed a recommendation that bivalirudin be
continued post procedure, although the protocol of “letting
the bag run out” provides variable treatment durations and
it is unclear how this impacted their outcomes.
More recently, the Minimizing Adverse Hemorrhagic
Events by Transradial Access Site and Systemic Imple-
mentation of Angiox (MATRIX) demonstrated a reduction in
secondary endpoints of bleeding and all-causemortality with
bivalirudin vs. heparin alone, but similar outcomes in pri-
mary combined endpoints.8 The largest of any of the trials
covered thus far, MATRIX randomized 7213 patients
to bivalirudin vs. heparindboth with equal use of bailout
GPIdand to radial vs. femoral access with downstream
randomization of bivalirudin to prolonged (>4 h) versus
immediately terminated post-procedure infusion. This trial
again revealed a slight increase in stent thrombosis rates
(1.0% vs. 0.6%; RR 1.71; 95% CI 1.00e2.93). The study has not
been published and the full analysis is not available, thus the
final word on whether or not a prolonged infusion strategy
works will have to wait.
But while the exact timing has not been elucidated in
randomized fashion, the currently available literature sug-
gests that if bivalirudin is selected, a high-dose infusion
should be considered for a minimum of 3 h post-procedure
in acute coronary syndromes. Though the cost effective-
ness of prolonged infusion has not been studied, this paper
and others suggest that bivalirudin treatment is associated
with net economic benefits.9 Despite higher up-front costs,
this strategy may help ensure that those patients with
the most to gain from bivalirudin may avoid its risks as well.r e f e r e n c e s
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